ETANERCEPT

CLASS: Antirheumatic, Disease Modifying; Tumor Necrosis Factor (TNF) Blocking Agent

INDICATIONS:

Treatment of moderately- to severely-active rheumatoid arthritis (RA); moderately- to severely-active polyarticular juvenile idiopathic arthritis (JIA); psoriatic arthritis; active ankylosing spondylitis (AS); moderate-to-severe chronic plaque psoriasis

AVAILABLE DOSAGE FROM THE HOSPITAL:

ETANERCEPT 25 MG INJ.

ETANERCEPT 50 MG INJ.dosage:

- **Dosing Adult:**
  Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis: SubQ:
  Once-weekly dosing: 50 mg once weekly
  Twice-weekly dosing: 25 mg given twice weekly (individual doses should be separated by 72-96 hours)
  Plaque psoriasis: SubQ:
  Initial: 50 mg twice weekly, 72-96 hours apart; maintain initial dose for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully)
  Maintenance dose: 50 mg once weekly

- **Dosing: Geriatric**
  SubQ: Refer to adult dosing. Although greater sensitivity of some elderly patients cannot be ruled out, no overall differences in safety or effectiveness were observed

- **Dosing: Renal Impairment**
  No dosage adjustment provided in manufacturer's labeling (has not been studied)

- **Dosing: Hepatic Impairment**
  No dosage adjustment provided in manufacturer's labeling (has not been studied)

COMMON SIDE EFFECT:

>10%:

Central nervous system: Headache (17% to 19%)

Dermatologic: Rash (3% to 13%)

Gastrointestinal: Abdominal pain (5%; children 19%), diarrhea (3% to 16%), vomiting (3%; children 13%)

Local: Injection site reaction (14% to 43%; bleeding, bruising, erythema, itching, pain, or swelling)

Respiratory: Respiratory tract infection (21% to 54%; upper: 38% to 65%), rhinitis (12%)

Miscellaneous: Infection (50% to 81%; children 62%), positive antidouble-stranded DNA antibodies (15% by RIA, 3% by Crithidia luciliae assay), positive ANA (11%)

PREGNANCY RISK FACTORS: B